je.st
news
Top healthcare stock fund focuses on costs, orphan drugs in 2016
2015-11-18 01:43:18| Biotech - Topix.net
Healthcare companies that can either contain costs or develop medications to treat rare diseases, known as orphan drugs, will be the most likely to outperform in the coming year, said John Fraunces, whose Turner Medical Sciences Long/Short fund is among the top performing healthcare funds over the last 5 years. Fraunces, who co-manages the $134 million fund, said he has been increasing his short positions, or bets that shares will decline, on companies that face increased price pressure for high-priced drugs.
Tags: top
stock
costs
fund
Category:Biotechnology and Pharmaceuticals